基蛋生物(603387.SH):景川診斷成為公司控股子公司
格隆匯 7 月 23日丨基蛋生物(603387.SH)公佈,全國中小企業股份轉讓系統有限責任公司於2020年5月29日出具了《關於景川診斷特定事項協議轉讓申請的確認函》(股轉系統函[2020]1295號)。2020年7月22日,公司收到中國證券登記結算有限責任公司出具的《景川診斷持股5%以上股東每日持股變化名單》,確認此次交易已於2020年7月21日完成了上述特定事項協議轉讓相關手續。股份過户登記完成後,公司持有景川診斷1868.7212萬股股份,佔景川診斷總股本的54.96%,景川診斷成為公司的控股子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.